J.P. Morgan Week, San Fransisco, USA, 9-12 January 2023.

Join us in San Francisco during the JPM Week on January 9-12, 2023.

BIO One-on-One Partnering™ returns to San Francisco for JPM Week 2023 with in-person meeting space at the San Francisco Marriott Marquis.

BIO One-on-One Partnering unifies access to partnering for the entire life science industry and allows you to efficiently arrange meetings with biotechs, investors, in-licensors, medical device, medtech companies and other life science leaders.

(November 2022)

Bio Europe Spring, Basel, Switzerland, 20-22 March 2023.

Join us for Europe's largest springtime partnering event.

BIO-Europe Spring 2023 brings together the life science community for global dealmaking in-person and digitally. The event will take place in-person on March 20-22 in Basel, Switzerland, as well as digitally on March 28-30. Xplico will be present at both events.

(November 2022)

LSX World Congress, London, England, 3-4 May 2023.

The 9th LSX World Congress on 3-4 May 2023 in London, UK, gathers the founders and CEOs of innovative start-ups through to healthcare giants, and everyone in between. It represents the breadth and depth of the cutting-edge research and technology driving the advances in the industry right now and in the near future.

It is an industry-leading gathering with qualified 1:1 partnering at its core, connecting the biotech, healthtech and medtech industry c-suite with the sector’s most active pharma, investors and health technology BD&L teams, R&D leaders, KOLs and top tier service companies who are driving the sector forward.

(November 2022)

BIO International Convention, Boston, USA, 5-8 June 2023.

The BIO International Convention attracts each year 10,000+ biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. The 2023 convention takes place in Boston on June 5-8, and offers the best opportunities for business development, networking events, along with expert-level programming content focused on the most pressing industry topics including COVID-19, infectious diseases, oncology, business development, financing trends, cell and gene therapy, digital health, and more.

(November 2022)

Xplico elected a Gazelle Company for the 4th year in a row

We are proud to announce that Xplico has been elected a Gazelle company for the 4th year in a row.

The election is organized by the Danish financial newspaper Børsen, and the requirements to become a Gazelle company are tough. A Gazelle business is continuously growing and, as a minimum, doubles its revenue or gross profit over four fiscal years, while maintaining positive growth throughout the years.

It is quite impressive that we have been able to live up to this four years in a row and we express our gratitude to our customers because without their continuous support and trust this would not have been possible.

(October 2019)

The new Xplico Evaluator template is now released

Xplico proudly releases a new and enhanced version of Xplico Evaluator, our valuation tool, available for all our subscription customers.

Many things have been changed behind the scene, with only a few changes in the way the assumptions are entered. The new version can handle more advanced Deal Terms and it has more features as well as additional outputs.

(June 2019)

Publication of the Xplico Valuation Survey

(November 2018)

Xplico article for Biotech & Money / LSX

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Finn Nikolajsen, gives his point of view on the challenges of the ownership structures that the biotech companies and their investors face when they try to analyze the consequences of current and future funding rounds and exits.

(October 2018)

Xplico article for Biotech & Money / LSX

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, gives his point of view on the challenges that the Nordic life science companies face.

(August 2018)

Xplico Interview with Biotech & Money / LSX

In an interview with Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, explains how valuation is critical for strategic decision-making and points out to some of the common pitfalls companies encounter when using valuation models that are built in house.

(June 2018)